Khiron Medical Cannabis Products Arrive in Germany Such as Immediate Prescription, Sale and Re – PRNewswire
- First Dispatch of Khiron branded EU-GMP certified medical cannabis into Germany successfully Finished, providing Prompt access to German Marketplace through Supply Spouse, Nimbus Health GmbH
- Launch Merchandise is Khiron 1/14 high-CBD flower, which will focus on Signs like anxiety, substance use disorder, along with migraines, addressing Individual needs and Enhancing Accessibility to medical cannabis
- Organization to leverage Venture with Nimbus Health GmbH, a Major EU-GMP/GDP certified medical cannabis distributor in Germany Using Community of over 300 pharmacies
- Khiron teams continue to Teach Doctors with Strategies to leverage clinical evidence from both the UK and Colombia
TORONTO, March 22, 2021 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the”Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America along with Europe, is pleased to announce that the Company has delivered EU-GMP medical cannabis merchandise to Germany. In collaboration using Nimbus Health, a major medical cannabis distributor in Germany, Khiron is currently positioned for imminent first sales in Germany. Khiron goods are currently in inventory in the Nimbus warehouse, ready to be prescribed to individuals and dispersed through a Huge network of 300 pharmacies around Germany.
This major milestone represents a brand new revenue stream for the Company and positions Khiron’s European team to execute on its German medical plan. Leveraging its partner’s large distribution network and Khiron’s continuing investments in physician education, the Company has secured immediate access into the German industry. Khiron 1/14 will concentrate on signs like stress, substance use disorder, and migraines, addressing patient needs and enhancing access to medical cannabis.
Tejinder Virk, President of Khiron Europe, remarked,”Since registering our distribution agreement with Nimbus Health in 2020, the provider’s European Sales and Marketing teams have been actively teaching doctors and increasing awareness for our goods. We’re excited to start our portfolio using Khiron 1/14, a item that covers unmet medical need from the German market. As we continue to expand our presence in the UK and Germanywe will leverage our clinical expertise from Colombia to provide the EU marketplace with additional cannabis-based medicinal products.”
Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe established in Frankfurt, remarked,”I’d love to thank our European team to their unwavering perseverance over the last couple of months; their efforts have allowed us to accomplish this significant milestone regardless of the challenges of the global pandemic and Germany’s rigorous regulatory atmosphere. Together with licenses in place and merchandise currently available for sale, we look forward to increasing our presence in this growing marketplace with over 60,000 medical cannabis individuals and a population of over 82 million people. We’re already developing additional cannabis-based medicinal products from our accredited strains recently imported from Colombia to enhance access and merchandise selection for German patients.”
Through its EU-GMP accredited supply chain partners in Europe, Khiron proceeds to expand its supply of world-class medical cannabis products, targeting the introduction of cannabis-based medicinal products according to these distributed by the organization in Colombia and Peru. Together with Khiron’s proof of concept currently affirmed in Colombia, the organization plans to leverage its own clinical information and IP, educational platforms, and technology and systems to expand into new markets.
Around Khiron Life Sciences Corp..
Khiron is the major medical cannabis provider in Colombia along with also the first firm licensed in Colombia for the cultivation, manufacturing, domestic distribution and revenue, and global export of the low and higher THC medical cannabis products. The Company has stuffed health cannabis prescriptions in Colombia, Peru along with also the United Kingdom, also is set to commence sales of medical cannabis in Mexico, Germany along with Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary telemedicine programs, Khiron combines a patient-oriented approach, doctor education programs, scientific expertise, product creation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare manufacturer in Colombia, with KuidaTM currently marketed in a number of authorities in Latin America, the US and United Kingdom. The Company is directed by Co-founder and Chief Executive Officer, Alvaro Torres, with a seasoned and diverse executive team and Board of Directors.
Go to Khiron online at investors.khiron.ca and around Instagram @khironlife.
All information included herein that isn’t historical in nature may constitute forward-looking details. Khiron undertakes no responsibility to comment on analyses, statements or expectations made from third-parties in respect of Khiron, its own securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions regarding future events which may prove to be erroneous and are subject to numerous risks and uncertainties, certain of which are outside Khiron’s management, including the risk factors discussed in Khiron’s yearly Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its own Regulation Services Provider (as the phrase is defined in the policies of this TSXV) takes responsibility for the adequacy or accuracy of this press release.